Aspire-Lakewood (ASBP) approves $10M buyback; DCSC 2025 revenue $209.5M, EBITDA $22.3M

Aspire Biopharma Holdings, Inc.

Name changed to Aspire-Lakewood Holdings, Inc. effective Sept 8, 2026; ticker remains ASBP.
Board authorized $10M common stock repurchase program effective Sept 9, 2026.
DCSC FY2025 revenue ~$209.5M, Adjusted EBITDA $22.3M; H1 2026 revenue $103.9M, EBITDA $10.5M.
~1.5M shares outstanding as of Sept 8, 2026; 2025 Adjusted EBITDA ~$15.00 per share.
CEO cites strong cash flow and undervaluation; buyback may be open market or private transactions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.